Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
- PMID: 20408862
- PMCID: PMC2940156
- DOI: 10.1111/j.1365-2249.2010.04141.x
Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
Abstract
The proportions and activation status of T cells may influence responses to hepatitis C virus (HCV) and treatment outcome in patients receiving pegylated interferon (IFN)-alpha/ribavirin therapy. We confirmed that IFN-gamma enzyme-linked immunospot (ELISPOT) responses to HCV are poor in HCV patients and showed that responses to HCV and cytomegalovirus (CMV) antigens decrease during therapy. This was most apparent in patients with sustained virological response (SVR). Baseline frequencies of CD4+ effector memory (TEM) T cells were lower in SVR than non-SVR. Proportions of CD4+ and CD8+ TEM and terminally differentiated effector memory (TEMRA) T cells declined on therapy in SVR, as did proportions of Fas+ CD8+ TEMRA T cells. Baseline frequencies of programmed death (PD)-1-expressing CD4+ TEM and TEMRA T-cells were higher in SVR. Therapy increased percentages of PD-1+ CD4+ central memory (TCM) T cells and PD-1+ CD8+ TEM and TEMRA T cells in SVR. We conclude that successful therapy depletes circulating antigen-specific CD4+ T cell responses. This paralleled decreases in proportions of effector memory T cells and higher percentages of CD4+ TCM T cells expressing PD-1.
Figures



Similar articles
-
Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.J Virol. 2008 Aug;82(15):7567-77. doi: 10.1128/JVI.02175-07. Epub 2008 May 14. J Virol. 2008. PMID: 18480446 Free PMC article.
-
T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.HIV Med. 2003 Apr;4(2):120-6. doi: 10.1046/j.1468-1293.2003.00140.x. HIV Med. 2003. PMID: 12702132 Clinical Trial.
-
Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.Antivir Ther. 2010;15(3):333-42. doi: 10.3851/IMP1531. Antivir Ther. 2010. PMID: 20516553 Clinical Trial.
-
Treatment of chronic hepatitis C in southern Taiwan.Intervirology. 2006;49(1-2):99-106. doi: 10.1159/000087271. Intervirology. 2006. PMID: 16166797 Review.
-
Immune responses during acute and chronic infection with hepatitis C virus.Clin Immunol. 2008 Aug;128(2):133-47. doi: 10.1016/j.clim.2008.03.525. Epub 2008 Jun 2. Clin Immunol. 2008. PMID: 18514579 Free PMC article. Review.
Cited by
-
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.J Immunol. 2018 Feb 1;200(3):1124-1132. doi: 10.4049/jimmunol.1701364. Epub 2017 Dec 20. J Immunol. 2018. PMID: 29263212 Free PMC article.
-
Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.Viruses. 2018 Aug 8;10(8):414. doi: 10.3390/v10080414. Viruses. 2018. PMID: 30096846 Free PMC article.
-
CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells.PLoS One. 2014 Jan 20;9(1):e85191. doi: 10.1371/journal.pone.0085191. eCollection 2014. PLoS One. 2014. PMID: 24465502 Free PMC article.
-
Decreases in activated CD8+ T cells in patients with severe hepatitis B are related to outcomes.Dig Dis Sci. 2015 Jan;60(1):136-45. doi: 10.1007/s10620-014-3297-x. Epub 2014 Aug 1. Dig Dis Sci. 2015. PMID: 25081223
References
-
- Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat. 2008;15:2–11. - PubMed
-
- Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–72. - PubMed
-
- Chang KM, Thimme R, Delpolder JJ, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2001;33:267–76. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous